Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS: −624.8%
Free cash flow: −108.8%

Quarter to September 2026, against a year earlier

102.07 5.48 +5.67%

Follow SYRE

Alert me

Market cap: $9.2B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −3.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Spyre Therapeutics, Inc. (SYRE) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Spyre Therapeutics, Inc. (SYRE) trades at a P/S ratio of 8,160×. Over the past ten years it has ranged from 0.4× (June 2016) to 8,756× (August 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SYRE/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Spyre Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SYRE/metrics/ps-ratio">Spyre Therapeutics, Inc. (SYRE) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2023	319×	1,989.68%
FY2022	15.3×	3.16%
FY2021	14.8×	(37.11%)
FY2018	23.5×	50.40%
FY2017	15.6×	61.70%
FY2016	9.7×	974.66%
FY2015	0.9×	—

Period	P/S ratio	Change
Dec 2023	319×	809.52%
Jun 2023	35.1×	49.38%
Mar 2023	23.5×	53.81%
Dec 2022	15.3×	78.73%
19 more quarters	Free account

Against its own ten years

Low 0.4× High 8,756×

Ten-year median 32.3×

Current reading's percentile 99

Company	P/S ratio
CAI Caris Life Sciences,�Inc. compare	7.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	8.2×
TGTX TG Therapeutics, Inc. compare	10.3×
TWST Twist Bioscience Corporation compare	17.6×
KRYS Krystal Biotech, Inc. compare	18.9×
PTGX Protagonist Therapeutics, Inc. compare	31.7×
IBRX ImmunityBio, Inc. compare	51.0×
CYTK Cytokinetics, Incorporated compare	64.4×
SYRE Spyre Therapeutics, Inc.	8,160×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Spyre Therapeutics, Inc. (SYRE) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on SYRE

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on SYRE

Stockrow Weekly